Tenaya Therapeutics is a biotechnology company. The Company was founded in 2016 by leading cardiovascular scientists from the David J. Gladstone Institutes and the University of Texas Southwestern Medical Center.
We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver curative therapies that address the underlying drivers of heart disease. Our vision is to change the treatment paradigm for heart disease, and in doing so improve and extend the lives of millions of individuals and families fighting this debilitating disease. We are advancing a pipeline of disease-modifying therapies developed using our product platforms and core internal capabilities to target defined sub-populations of patients with rare or highly prevalent forms of heart disease.
We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver curative therapies that address the underlying drivers of heart disease. Our vision is to change the treatment paradigm for heart disease, and in doing so improve and extend the lives of millions of individuals and families fighting this debilitating disease. We are advancing a pipeline of disease-modifying therapies developed using our product platforms and core internal capabilities to target defined sub-populations of patients with rare or highly prevalent forms of heart disease.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $198M
Founded date: 2016
Investors 4
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.03.2021 | Series C | $106M | - |
| 03.10.2019 | Series B | $92M | - |
Mentions in press and media 17
| Date | Title | Description |
| 17.10.2024 | Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM | Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024 Highlights Recently Presented Insights on Pediat... |
| 08.08.2024 | Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing of TN-401 for PKP2-Associated Arrhythmogenic ... |
| 18.03.2024 | Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in Second Half 2024 $47 Mi... |
| 02.03.2021 | Tenaya Therapeutics secures $106M | Tenaya Therapeutics has raised a $106 million Series C led by RTW Investments. The Bay Area company is developing therapies to address cardiovascular disease, with a focus on gene therapy, cellular regeneration and precision medicine. Tenay... |
| 02.03.2021 | Tenaya Therapeutics Secures $106M in Series C | SOUTH SAN FRANCISCO, CA, Tenaya Therapeutics, announced that it has secured $106 million in Series C funding. >> Click here for more funding data on Tenaya Therapeutics >> To export Tenaya Therapeutics funding data to PDF an... |
| 01.03.2021 | Daily funding roundup - March 1st, 2021 | Skydio raised $170M; Artiva landed $120M; FogPharma secured $107M; Axonius picks up $100M Skydio: Skydio is a Redwood City, Ca.-based autonomous drone-maker. Skydio has raised $170 million in Series D funding at a post-money valuation of mo... |
| 01.03.2021 | Tenaya grabs $106M top-up to push heart disease gene therapies to the clinic | With another $106 million in the bank, heart-focused Tenaya Therapeutics is ready to talk targets. The series C funding will propel several preclinical programs toward the clinic, including a gene therapy for hypertrophic cardiomyopathy (HC... |
| 01.03.2021 | Tenaya Therapeutics Raises $106M in Series C Funding | Tenaya Therapeutics, a South San Francisco, CA-based biotechnology company to discover, develop and deliver curative therapies that address the underlying causes of heart disease, secured $106m in Series C funding. The round was led by RTW ... |
| 01.03.2021 | Tenaya grabs $106M top-up to push heart disease gene therapies to the clinic W e b i n a r Enabling Individuals to Act on Heart Health Insights | With another $106 million in the bank, heart-focused Tenaya Therapeutics is ready to talk targets. The series C funding will propel several preclinical programs toward the clinic, including a gene therapy for hypertrophic cardiomyopathy (HC... |
| 11.10.2019 | Tenaya Therapeutics Raises $92 Million In Funding To Deliver Curative Heart Disease Therapies | Tenaya Therapeutics, a company that is aiming to discover, develop, and deliver curative therapies that target the underlying causes of heart disease, has raised $92 million Tenaya Therapeutics — a company with a mission to discover, develo... |
Show more